SUMMARY
anaesthetic, or causes any measurable variation in circulatory responses.
PATIENTS AND METHODS
The study included 27 neurosurgical patients (ASA groups I-III) prepared for trepanation. Patients with severe impairment of the cardiovascular system were not admitted to the study.
After induction of a standardized, modified neuroleptanaesthetic technique, the surgeon infiltrated the scalp area intended for trepanation with 40 ml of the solution to be tested. Care was taken to avoid intravascular injection.
The patients were allocated randomly to the following groups: Saline group (n = 10): 2% lignocaine with adrenaline 1:50000, diluted 1:1 with 0.9% saline solution.
Dextran group (n = 10): 2% lignocaine with adrenaline 1:50000, diluted 1:1 with 6% dextran 60 in 0.9 % saline solution (Plasmafusin 60). Control group (« = 7): 0.9% saline solution.
The pH-values of the two local anaesthetic solutions were 3.65.
All samples were taken from a central venous catheter at the following intervals: 51 = Immediately before injection 52 = 5 min after injection 53 = 10 min after injection 54 = 20 min after injection 55 = 30 min after injection 56 = 45 min after injection 57 = 60 min after injection Plasma adrenaline and noradrenaline, and serum lignocaine concentrations were measured.
Heart rate and arterial pressure were monitored continuously after cannulation of a radial artery.
The determination of plasma catecholamines by high pressure liquid chromatography with electrochemical detection (HPLC-ECD) and of lignocaine by gas chromatography have been reported elsewhere [8] [9] [10] .
The catecholamine and lignocaine values were log-transformed and evaluation was undertaken using the geometric mean values. Values of arterial pressure and heart rate are expressed as arithmetic mean. Statistical differences were determined using analysis of variance with repeated measures on one factor. P values less than 0.05 were considered significant. (table I) The concentrations of plasma adrenaline in the dextran group were significantly lower than those in the saline group (P < 0.0001).
RESULTS

Plasma adrenaline
Differences in time courses of concentrations between both groups were also apparent (P < 0.0001). Figure 1 illustrates the time course of adrenaline concentrations in all three groups, demonstrating main differences 5-20 min after the end of injection. A close approximation of the curves was achieved 60 min after the end of injection. Serum lignocaine (table I) The concentrations of lignocaine in the dextran group were significantly lower than those in the saline group (P < 0.0001). Differences in time course between the groups were also observed (P < 0.0001). Figure 1 demonstrates a similar time course of adrenaline and lignocaine concentrations within the treatment groups. Plasma noradrenaline (table I) There were no differences between the test groups in noradrenaline concentrations and time course. No significant change in noradrenaline concentrations within the test groups was observed ( fig. 2) . (table II) There were no significant differences in mean 95 (18) 102 (8) 100 (12) 95 (15) 99 (7) 100 (12) 90 (15) 95 (9) 103 (16) 85 (14) 94 (15) 92 (10) 88 (15) 94 (13) 91 (9) 90 (15) 94 (15) 90 (7) 92 (13) 95 (12) 90 (10) HR (beat min" 1 ) 71 (11) 65 (12) 73 (12) 82 (19) 68 (13) 74 (12) 81 (17) 67 (12) 77 (9) 78 (15) 66 (11) 79 (13) 73 (10) 66 (10) 78 (11) 70 (5) 64 (9) 75 (8) 68 (6) 65 ( arterial pressure with respect to mean values and course of time ( fig. 3 ).
Mean arterial pressure
Heart rate (table II) Differences in mean values of heart rate were not significantly different (P = 0.08), but the changes in time course did reach statistical significance (P = 0.04). Figure 3 shows the higher values of heart rate in the saline group compared with the dextran group, particularly 5-20 min after injection.
DISCUSSION
In addition to the studies noted above, other investigators have also examined the effects of a dextran adjuvant on the duration of action and the absorption of local anaesthetic solutions.
In 1967, Chinn and Wirjoatmadja [11] observed that the addition of dextran in ulnar blocks prolonged objective anaesthesia by 10-20%. They proposed that this might result from the formation of a loose complex between the dextran macromolecules and the local anaesthetic.
Kaplan, Miller and Gallagher [12] used low molecular weight dextran (dextran 40) to supplement 0.75 % bupivacaine in intercostal blocks. They found that the mean duration of action of this solution was approx. 36 h; when bupivacaine was administered alone it was less than 12 h.
Whereas previous investigators used only clinical criteria, more sophisticated animal experiments were performed in 1978 by Aberg, Friberger and Sydnes [13] . They demonstrated that the absorption of radioactive labelled mepivacaine was delayed by the addition of dextran; this was attributed to the formation of water-soluble complexes of dextran and the local anaesthetic. However, the authors could not confirm these results in tests involving dental infiltration anaesthesia. They concluded that this phenomenon was caused by poor diffusibility of the solution to its site of action within the alveolar process. They also reported that the addition of dextran reduced the acute toxicity (LD 50 ) of mepivacaine in mice after subcutaneous application, but not when administered by i.v. injection.
Other clinical trials and animal experiments have not provided conclusive results, or demonstrated any synergistic dextran effect [14] [15] [16] [17] [18] . It is worth noting that, in all these studies, low molecular weight dextran was used. However, other authors have found the combination to be BRITISH JOURNAL OF ANAESTHESIA effective [19] . Further investigations were performed using mixtures of dextran and local anaesthetic in different ratios [20] , dextrans of high and low molecular weight [21] [22] [23] and solutions with various pH values. Some studies concluded that the effect of the addition of dextran was caused by increasing alkalization of the solution and that molecular weight was not an important factor [24, 25] . In a dialysis model, these authors were able to demonstrate that the addition of dextran did not reduce the elimination of bupivacaine [24] . Similar results were obtained by Scurlock and Curtiss [26] . Investigations of a Scandinavian group [27] [28] [29] [30] did provide evidence for the activity of dextran when used to supplement prilocaine, but not bupivacaine. They, too, ascribed this effect to an increase in viscosity.
Ueda, Hirakawa and Mori [31, 32] demonstrated that dextran inhibited the absorption of adrenaline. Lignocaine increased the systemic concentrations of adrenaline, which the authors ascribed to the vasodilator effect of lignocaine, but it was possible to mitigate this effect by the addition of dextran. This study, however, was not performed during standardized anaesthesia; the observation period lasted only 30 min and the authors did not specify from which site blood samples were drawn for catecholamine analysis.
The present study was designed to investigate the effect of a dextran adjuvant on the absorption of a local anaesthetic solution under standardized clinical conditions over a longer observation period in patients during modified neuroleptanaesthesia. The simultaneous determination of adrenaline and lignocaine concentrations using lignocaine as an internal standard should provide reliable results with regard to patterns of absorption and length of time for which the active substance remains at the site of injection.
According to the plasma noradrenaline concentrations in both test groups and the concentrations of adrenaline and noradrenaline in the control group, surgical stress had no evident influence on the course of anaesthesia. Therefore the adrenaline concentrations recorded in the two test groups reflect the process of absorption at the site of injection.
The adrenaline concentrations exceed other results reported in the literature [33, 34] , although there was no clinical evidence for intravascular injection.
The addition of 6 % dextran to the lignocaine solution containing adrenaline caused a definite reduction in uptake of the catecholamine from its injection depot. This effect reduced the high initial concentrations and led to a prolonged, continuous absorption.
The dextran adjuvant had a similar effect on the uptake of lignocaine. The lignocaine concentrations were markedly reduced and extended over a long period without wide variations. Although the time course of clinical effects was not investigated in this study, it may be assumed that the delayed absorption of the solution is accompanied by a prolonged duration of action.
Under the conditions described here, the different absorption patterns of the two solutions had no obvious effect on mean arterial pressure. Comparable local anaesthesia in awake patients may lead to other results. Nevertheless, differences in heart rate were evident in the present study.
The following conclusions may be drawn regarding clinical practice: (1) Because of its absorption-reducing action, the addition of dextran to adrenaline-containing solutions may protect against toxic systemic side effects of both adrenaline and lignocaine. (2) This effect is of particular significance in patients with cardiovascular and endocrine disorders and in patients who are susceptible to convulsions. (3) The dextran adjuvant may reduce toxicity resulting from administration of adrenaline-containing local anaesthetic solutions in patients during inhalation anaesthesia, especially with halothane. (4) Since the local anaesthetic solution remains for a longer time at the site of injection, a prolonged duration of action may also be expected.
